Market Cap (In AUD)
2.17 Million
Revenue (In AUD)
-
Net Income (In AUD)
-933.87 Thousand
Avg. Volume
621.44 Thousand
- Currency
- AUD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.008-0.021
- PE
- -
- EPS
- -
- Beta Value
- 0.916
- ISIN
- AU0000111932
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Geoffrey Paul Kempler B.Sc.
- Employee Count
- -
- Website
- https://www.hexima.com.au
- Ipo Date
- 2020-11-30
- Details
- Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is the plant defensin, pezadeftide, which is in phase IIb clinical trials for the treatment of fungal toenail infections in Australia and New Zealand. Hexima Limited was incorporated in 1997 and is based in Preston, Australia.
More Stocks
-
SESNSesen Bio, Inc.
SESN
-
ATMCW
-
LVVV
-
AEXFFAminex PLC
AEXFF
-
300102Xiamen Changelight Co., Ltd.
300102
-
PTOSP2 Solar, Inc
PTOS
-
CRVOCervoMed Inc.
CRVO
-
CRGX